GKB Ophthalmics Intrinsic Value
GKB Ophthalmics (GKB) median intrinsic value is ₹134.34 from 9 valuation models (range ₹74–₹202), vs current price ₹67.17 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit GKB share price.
GKB Valuation Methods Summary — DCF, Graham Number & P/E
GKB Ophthalmics intrinsic value across 9 models vs current price ₹67.17 — upside/downside and value range per method. Browse GKB balance sheet details for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹201.51 | ₹161.21 - ₹241.81 | +200.0% | EPS: ₹12.68, Sector P/E: 22x |
| Book Value Method | asset | ₹167.93 | ₹151.14 - ₹184.72 | +150.0% | Book Value/Share: ₹112.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹134.34 | ₹120.91 - ₹147.77 | +100.0% | Revenue/Share: ₹248.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹134.34 | ₹120.91 - ₹147.77 | +100.0% | EBITDA: ₹12.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹74.27 | ₹59.42 - ₹89.12 | +10.6% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹81.15 | ₹73.04 - ₹89.27 | +20.8% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹195.91 | ₹176.32 - ₹215.50 | +191.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹134.34 | ₹120.91 - ₹147.77 | +100.0% | ROE: 14.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹178.76 | ₹160.88 - ₹196.64 | +166.1% | EPS: ₹12.68, BVPS: ₹112.00 |
GKB Intrinsic Value vs Market Price — All Valuation Models
GKB Ophthalmics fair value range ₹74–₹202 vs current market price ₹67.17 across 9 valuation models. Compare with GKB fair price to assess whether the stock is under or overvalued.
GKB Intrinsic Value Analysis — Undervalued or Overvalued?
GKB Ophthalmics median intrinsic value ₹134.34, current price ₹67.17 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of GKB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of GKB Ophthalmics (GKB) is ₹134.34 (median value). With the current market price of ₹67.17, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹74.27 to ₹201.51, indicating ₹74.27 - ₹201.51.
Is GKB undervalued or overvalued?
Based on our multi-method analysis, GKB Ophthalmics (GKB) appears to be trading below calculated value by approximately 100.0%.
GKB Financial Health — Key Ratios vs Industry Benchmarks
GKB Ophthalmics financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 16.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 10.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.99x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GKB Cash Flow Quality — Operating & Free Cash Flow
GKB Ophthalmics operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹5 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹7 Cr | ₹-2 Cr | Positive Operating Cash Flow | 6/10 |